This was partly highlighted in the CANTOS Trial in patients with atherosclerotic disease: targeting IL-1β-mediated pathway through administration of canakinumab had the beneficial effect of significantly decrease major adverse cardiovascular events, but with increased risk of fatal infections compared with placebo [214]. This evidence concerns the gene IL1B and infection.